The identification of SYK as a master regulator of anti-apoptotic signaling in B-lineage leukemia/lymphoma cells prompted the development of SYK inhibitors as a new class of anti-cancer drug candidates (Uckun and Qazi, 2010, D'Cruz and Uckun, 2012, Myers et al., 2014, Uckun et al., 2013, Perova et al., 2014, Wang et al., 2014, Geahlen, 2014). This evidence concerns the gene SYK and cancer.